MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-10-2025
Isoray Income Statement 2011-2026 | ISR
Annual Income Statement Isoray
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
24.5 M | 10.2 M | 42.6 M | 53.9 M | 115 M | 25.5 M | 36.4 M | 33.6 M | 42.4 M | 75.7 M | 109 M | 21 M | 31.2 M | 25.9 M |
Shares |
64.4 M | 26.8 M | 142 M | 142 M | 67.6 M | 67 M | 55.2 M | 55 M | 55 M | 54.9 M | 42.7 M | 34.4 M | 28.6 M | 25.1 M |
Historical Prices |
0.38 | 0.38 | 0.3 | 0.38 | 1.7 | 0.8 | 0.45 | 0.48 | 0.6 | 0.72 | 1.34 | 0.74 | 0.71 | 0.63 |
Net Income |
-79.3 M | -46.5 M | -7.34 M | -3.85 M | -3.45 M | -5.14 M | -6.7 M | -6.16 M | -4.71 M | -3.68 M | -5.96 M | -3.86 M | -3.49 M | -2.84 M |
Revenue |
- | - | 3.55 M | 5.38 M | 9.68 M | 7.31 M | 5.92 M | 4.76 M | 4.77 M | 4.61 M | 4.22 M | 4.53 M | 5.07 M | 5.24 M |
Cost of Revenue |
- | - | - | 3.13 M | 4.56 M | 4.27 M | 4.08 M | 3.92 M | 4.64 M | - | - | - | - | - |
Gross Profit |
- | - | 817 K | 2.25 M | 5.12 M | 3.05 M | 1.84 M | 838 K | 129 K | 167 K | -196 K | 150 K | 703 K | 1.16 M |
Operating Income |
-90.9 M | -40.9 M | -5.62 M | -3.91 M | -3.48 M | -5.25 M | -6.73 M | -6.31 M | -5.08 M | -4.34 M | -4.59 M | -4.07 M | -3.6 M | -2.96 M |
Interest Expense |
- | - | - | - | - | 2 K | - | - | 950 | 2.21 K | 883 | 7 | - | - |
EBITDA |
-88.6 M | -40 M | -5.48 M | -3.79 M | -3.33 M | -5.09 M | -6.6 M | -6.19 M | -4.5 M | -3.72 M | -3.87 M | -3.33 M | -2.75 M | -2.07 M |
Operating Expenses |
92.3 M | 42.4 M | 5.62 M | 6.16 M | 8.6 M | 8.32 M | 8.57 M | 7.14 M | 5.21 M | 4.5 M | 4.39 M | 4.22 M | 4.3 M | 4.12 M |
General and Administrative Expenses |
26.6 M | 21.1 M | 4.85 M | 3.46 M | 4.57 M | 4.17 M | 4.16 M | 3.92 M | 3.79 M | 2.4 M | 2.49 M | 2.29 M | 2.36 M | 2.42 M |
All numbers in USD currency
Quarterly Income Statement Isoray
| 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
74.3 M | 74.2 M | 70.7 M | 70.6 M | 66.6 M | 495 M | 28.2 M | 28.1 M | 28 M | 229 M | 142 M | 142 M | 142 M | 142 M | 142 M | 142 M | 142 M | 123 M | 83 M | 68.9 M | 83 M | 68.9 M | 67.4 M | 67.4 M | 67.4 M | 67.4 M | 67.3 M | 66.1 M | 67.3 M | 66.1 K | 55.1 M | 55 M | 55.1 M | 55 M | 55 M | 55 M | 55 M | 55 M | 55 M | 55 M | 55 M | 55 M | 54.9 M | 54.9 M | 54.9 M | 54.9 M | 38.4 M | 35.9 M | 38.4 M | 35.9 M | 34.6 M | 33.9 M | 34.6 M | 33.9 M | 28.6 M | 26.5 M | 26.4 M | 26.4 M |
Net Income |
-26 M | -21.5 M | - | -15.1 M | -11.7 M | -12.3 M | - | -10.4 M | -11.1 M | -371 K | - | -4.07 M | -2.08 M | -1.35 M | -1.6 M | -2.24 M | -1.6 M | -2.24 M | -868 K | -868 K | -868 K | -713 K | -897 K | -897 K | -897 K | -816 K | -1.41 M | -1.41 M | -1.41 M | -1.51 M | -1.46 M | -1.55 M | -1.46 M | -1.55 M | -1.45 M | -1.5 M | -1.45 M | -1.5 M | -1.31 M | -1.02 M | -1.31 M | -1.02 M | -907 K | -786 K | -907 K | -786 K | -927 K | -1.27 M | -927 K | -1.27 M | -1.15 M | -994 K | -1.15 M | -994 K | -629 K | -1.1 M | -629 K | -1.1 M |
Revenue |
- | - | - | - | - | - | - | 2.18 M | 2.09 M | 2.06 M | - | 1.72 M | 2.5 M | 2.91 M | 2.82 M | 2.56 M | 2.71 M | 2.6 M | 2.36 M | 2.38 M | 2.28 M | 2.88 M | 2.21 M | 2.32 M | 1.92 M | 1.92 M | 1.9 M | 1.56 M | 1.9 M | 1.56 M | 1.54 M | 1.21 M | 1.37 M | 1.28 M | 1.03 M | 1.08 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
- | - | - | - | - | - | - | 1.45 M | 1.84 M | 1.58 M | - | 1.3 M | 1.58 M | 1.47 M | 1.6 M | 1.54 M | 3.13 M | 1.24 M | 1.19 M | 1.14 M | 1.19 M | 1.14 M | 1.1 M | 1.08 M | 1.1 M | 1.08 M | 1.14 M | 1.04 M | 1.14 M | 1.04 M | 1 M | 946 K | - | 989 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | - | - | 738 K | 248 K | 487 K | - | 414 K | 926 K | 1.44 M | 1.22 M | 1.03 M | 2.25 M | 1.36 M | 1.17 M | 1.25 M | 1.17 M | 1.25 M | 1.11 M | 1.24 M | 1.11 M | 1.24 M | 765 K | 524 K | 765 K | 524 K | 531 K | 265 K | 531 K | 265 K | -1 K | 48 K | -1 K | 48 K | 30 K | 83 K | 26.9 K | 83.5 K | -38 K | -54.8 K | -38 K | -54.8 K | -33.9 K | -77.3 K | -33.9 K | -77.3 K | -159 K | -20.4 K | -159 K | -20.4 K | 199 K | 66.3 K | 199 K | 66.3 K |
Operating Income |
-27.9 M | -24 M | - | -18.6 M | -14.3 M | -13 M | - | -9.75 M | -9.75 M | -9.76 M | - | -4.21 M | -2.11 M | -1.38 M | -1.64 M | -2.27 M | -3.91 M | -766 K | -873 K | -714 K | -873 K | -714 K | -903 K | -836 K | -903 K | -836 K | -1.43 M | -1.52 M | -1.43 M | -1.52 M | -1.47 M | -1.55 M | -1.47 M | -1.55 M | -1.48 M | -1.58 M | -1.48 M | -1.58 M | -1.41 M | -1.09 M | -1.41 M | -1.09 M | -1.02 M | -1.16 M | -1.02 M | -1.16 M | -1.04 M | -1.23 M | -1.04 M | -1.23 M | -1.1 M | -1.12 M | -1.1 M | -1.12 M | -792 K | -1.1 M | -792 K | -1.1 M |
Interest Expense |
- | - | - | - | - | - | - | 14 K | 28 K | 18 K | - | - | - | - | - | - | - | - | - | - | - | - | - | 2 K | - | 2 K | - | - | - | - | - | - | - | - | - | - | - | - | - | 950 | 950 | 100 | - | 3.45 K | 3.45 K | 3.45 K | 86 | 741 | - | - | - | - | - | - | - | - | - | - |
EBITDA |
- | - | - | - | - | -12.7 M | - | -9.49 M | -9.5 M | -9.58 M | - | -4.14 M | -2.03 M | -1.3 M | -1.64 M | -2.22 M | -3.79 M | -766 K | -873 K | -680 K | -802 K | -680 K | -903 K | -798 K | -826 K | -798 K | -1.43 M | -1.49 M | -1.36 M | -1.49 M | -1.47 M | -1.53 M | -1.43 M | -1.53 M | -1.48 M | -1.56 M | -1.45 M | -1.58 M | -1.27 M | -954 K | -1.14 M | -954 K | -885 K | -991 K | -715 K | -991 K | -1.04 M | -1.06 M | -695 K | -1.06 M | -1.1 M | -916 K | -711 K | -916 K | -792 K | -886 K | -357 K | -886 K |
Operating Expenses |
28.1 M | 24.3 M | - | 19 M | 14.8 M | 13.3 M | - | 10 M | 10.3 M | 9.99 M | - | 4.62 M | 3.03 M | 2.82 M | 2.86 M | 3.3 M | 6.16 M | 2.13 M | 2.04 M | 1.96 M | 2.04 M | 1.96 M | 2.01 M | 2.07 M | 2.01 M | 2.07 M | 2.19 M | 2.04 M | 2.19 M | 2.04 M | 2 M | 1.82 M | 2 M | 1.82 M | 1.48 M | 1.62 M | 1.48 M | 1.62 M | 1.44 M | 1.17 M | 1.44 M | 1.17 M | 982 K | 1.11 M | 982 K | 1.11 M | 1.01 M | 1.16 M | 1.01 M | 1.16 M | 941 K | 1.1 M | 941 K | 1.1 M | 991 K | 1.17 M | 991 K | 1.17 M |
General and Administrative Expenses |
7.73 M | 7.71 M | - | 6.98 M | 5.51 M | 5.88 M | - | 4.47 M | 4.99 M | 6.66 M | - | 3.11 M | 1.58 M | 1.58 M | 1.62 M | 1.84 M | 3.46 M | 1.18 M | 1.13 M | 1.07 M | 1.13 M | 1.07 M | 1.07 M | 1.1 M | 1.07 M | 1.1 M | 1.1 M | 973 K | 1.1 M | 973 K | 985 K | 841 K | 985 K | 841 K | 880 K | 927 K | 880 K | 927 K | 1.12 M | 752 K | 1.12 M | 752 K | 538 K | 576 K | 538 K | 576 K | 514 K | 651 K | 514 K | 651 K | 470 K | 645 K | 470 K | 645 K | 497 K | 653 K | 497 K | 653 K |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Isoray (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Medical instruments industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Becton, Dickinson and Company
BDX
|
$ 202.55 | -0.1 % | $ 58.3 B |  USA |
 |
Atrion Corporation
ATRI
|
- | - | $ 810 M | USA |
 |
Baxter International
BAX
|
$ 19.79 | -1.81 % | $ 10.1 B | USA |
 |
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | USA |
 |
ICU Medical
ICUI
|
$ 147.96 | -2.17 % | $ 3.61 B | USA |
 |
InfuSystem Holdings
INFU
|
$ 8.55 | -2.17 % | $ 177 M | USA |
 |
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
$ 8.0 | -8.88 % | $ 161 M | USA |
 |
Repro Med Systems
KRMD
|
$ 5.71 | -3.06 % | $ 260 M | USA |
 |
Alcon
ALC
|
$ 80.33 | -0.66 % | $ 40.4 B |  Schweiz |
 |
Masimo Corporation
MASI
|
$ 132.55 | 0.24 % | $ 7.06 B | USA |
 |
AtriCure
ATRC
|
$ 37.53 | -0.28 % | $ 1.76 B | USA |
 |
Merit Medical Systems
MMSI
|
$ 82.88 | -0.44 % | $ 4.83 B | USA |
 |
electroCore
ECOR
|
$ 6.38 | 0.79 % | $ 35.2 K | USA |
 |
AngioDynamics
ANGO
|
$ 9.94 | -2.36 % | $ 406 M | USA |
 |
The Cooper Companies
COO
|
$ 82.85 | -0.46 % | $ 16.5 B | USA |
 |
LeMaitre Vascular
LMAT
|
$ 83.63 | -0.24 % | $ 1.88 B | USA |
 |
Haemonetics Corporation
HAE
|
$ 78.66 | -5.14 % | $ 3.96 B | USA |
 |
Harvard Bioscience
HBIO
|
$ 0.6 | -3.64 % | $ 25.5 M | USA |
 |
OraSure Technologies
OSUR
|
$ 2.63 | -2.42 % | $ 196 M | USA |
 |
Glaukos Corporation
GKOS
|
$ 110.1 | -0.73 % | $ 5.33 B | USA |
 |
iRhythm Technologies
IRTC
|
$ 153.55 | -9.14 % | $ 4.79 B | USA |
 |
STERIS plc
STE
|
$ 259.24 | -0.59 % | $ 25.6 B | USA |
 |
Intuitive Surgical
ISRG
|
$ 565.9 | -1.2 % | $ 201 B | USA |
 |
Microbot Medical
MBOT
|
$ 2.09 | -2.11 % | $ 21.3 M |  Israel |
 |
Utah Medical Products
UTMD
|
$ 59.88 | - | $ 217 M | USA |
 |
Nephros
NEPH
|
$ 4.57 | 0.66 % | $ 47.5 M | USA |
 |
Milestone Scientific
MLSS
|
$ 0.29 | -0.55 % | $ 23.1 M | USA |
 |
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | USA |
 |
Envista Holdings Corporation
NVST
|
$ 23.19 | -0.83 % | $ 3.99 B | USA |
 |
Predictive Oncology
POAI
|
$ 6.94 | 0.51 % | $ 37.8 M | USA |
 |
Pro-Dex
PDEX
|
$ 40.48 | -6.45 % | $ 133 M | USA |
 |
Pulse Biosciences
PLSE
|
$ 14.18 | -2.68 % | $ 681 M | USA |
 |
Repligen Corporation
RGEN
|
$ 167.12 | -0.76 % | $ 9.31 M | USA |
 |
ResMed
RMD
|
$ 258.5 | 0.26 % | $ 37.8 B | USA |
 |
BioLife Solutions
BLFS
|
$ 24.15 | 0.46 % | $ 1.11 B | USA |
 |
Stereotaxis
STXS
|
$ 2.57 | 0.39 % | $ 207 M | USA |
 |
Retractable Technologies
RVP
|
$ 0.75 | -1.32 % | $ 22.5 M | USA |
 |
STAAR Surgical Company
STAA
|
$ 21.51 | -2.27 % | $ 1.06 B | USA |
 |
Teleflex Incorporated
TFX
|
$ 107.55 | -0.93 % | $ 5.04 B | USA |
 |
West Pharmaceutical Services
WST
|
$ 273.86 | 0.4 % | $ 20 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
$ 12.11 | -3.16 % | $ 2.46 B | USA |